



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AUG 20 2004

RECEIVED 1600

In re Patent Application of

von BORSTEL et al

Atty. Ref.: 1331-138

Serial No. 08/460,186

Group: 1623

Filed: June 2, 1995

Examiner: Owens, H.

For: TREATMENT OF CHEMOTHERAPEUTIC AGENT AND
ANTIVIRAL AGENT TOXICITY WITH ACYLATED
PYRIMIDINE NUCLEOSIDES

* * * * *

July 23, 2004

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT


Attached is a completed Form PTO-1449 listing three references mentioned in the response filed July 23, 2004. While no fee is believed to be required, the Commissioner is hereby authorized to charge our Deposit Account No. 14-1140 for any fee required in connection with the filing of this Information Disclosure Statement.

The Examiner is requested to initial the attached PTO-1449, and to return a copy of the initialed document to the undersigned as an indication that the listed references have been considered and made of record.


Respectfully submitted,

NIXON & VANDERHUYE P.C.

By:


Leonard C. Mitchard
Reg. No. 29,009

LCM:lks
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100



**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

1331-138

08/460,186

APPLICANT

von BORSTEL et al

FILING DATE

GROUP

June 2, 1995

1623

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Kralovanszky et al., Cancer Chemotherapy and Pharmacology, 1993, Vol. 32: 243-248, "Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high dose uridine".
	Calabresi et al., Blood, 1990, Vol. 76, No. 11: 2210-2215, "Benzylacetylouridine Reverses Azidothymidine-Induced Marrow Suppression Without Impairment of Anti-Human Immunodeficiency Virus Activity".
	Davis et al., Biochemical Pharmacology 1993, Vol. 45 No. 1: 173-181, "Species Dependent Differences in the Biochemical Effects and Metabolism of 5-Benzylacetylouridine".

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.